论文部分内容阅读
目的:分析不同剂量米非司酮治疗围绝经期子宫肌瘤诱导绝经的临床效果。方法:选择了120例围绝经期子宫肌瘤诱患者,将其随机分为三组(A组、B组、C组),每组患者40例,采用了不同剂量米非司酮的治疗方式,对其临床结果进行了对比分析。结果:通过研究发现,不同计量米非司酮诱导绝经所出现的不良反应存在差异,其中A组诱导成功的比例相对较高为80%,A组诱导绝经率高于B组以及C组,差差异具有统计学意义(P<0.05)。研究中对三组患者治疗前后的血红蛋白、子宫体积、子宫肌瘤体积进行了对比,C组发病率明显高于A组、B组,数据统计无明显差异,具有统计学意义(P<0.05)。结论:每日服用10mg/d的米非司酮使有效的最低剂量,可以避免不良反应的出现,因此,在临床医学中可以得到推广。
Objective: To analyze the clinical effects of different doses of mifepristone on perimenopausal uterine fibroids induced menopause. Methods: A total of 120 patients with uterine fibroids during perimenopausal period were selected and randomly divided into three groups (group A, group B and group C), 40 patients in each group were treated with different doses of mifepristone , The clinical results of a comparative analysis. Results: The study found that different doses of mifepristone induced menopausal differences in the emergence of adverse reactions, of which A group of successful induction of a relatively high proportion of 80%, A group of induced menopause rate was higher than the B group and C group, poor The difference was statistically significant (P <0.05). The study compared the three groups of patients before and after treatment of hemoglobin, uterine volume, uterine fibroids volume was compared, the incidence of C group was significantly higher than the A group, B group, no significant difference in statistical data, with statistical significance (P <0.05) . CONCLUSIONS: Taking 10 mg / day of mifepristone daily for the lowest effective dose avoids the emergence of adverse reactions and is therefore being promoted in clinical medicine.